The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.
The company said that an increase in clinical genetic testing volume contributed to overall revenue growth.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.
Clinical testing revenues inched up less than 1 percent, while pharma services revenues rose 38 percent, the company said.
The firm said that revenues for the third quarter is expected to be $63.1 million, which would be a 4 percent increase from the year-ago figure.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
NeoGenomics' clinical genetic testing revenues were up 7 percent year over year, as the number of genetic tests completed increased by 16 percent.
The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.